このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MaxCyte 過去の業績

過去基準チェック /06

MaxCyteの収益は年間平均-27.6%の割合で減少していますが、 Life Sciences業界の収益は年間増加しています。収益は年間19.6% 18.1%割合で増加しています。

主要情報

-27.6%

収益成長率

-11.4%

EPS成長率

Life Sciences 業界の成長	36.9%
収益成長率	18.1%
株主資本利益率	-16.2%
ネット・マージン	-83.0%
前回の決算情報	31 Mar 2024

Recent updates

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

If You Had Bought MaxCyte (LON:MXCT) Shares A Year Ago You'd Have Earned 249% Returns

Nov 24

収支内訳

MaxCyte の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

AIM:MXCT 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	44	-37	58	24
31 Dec 23	41	-38	57	24
30 Sep 23	38	-37	53	24
30 Jun 23	41	-33	50	23
31 Mar 23	41	-30	48	22
31 Dec 22	44	-24	44	20
30 Sep 22	42	-24	44	17
30 Jun 22	41	-20	41	15
31 Mar 22	39	-16	36	13
31 Dec 21	34	-19	32	15
30 Sep 21	32	-17	26	17
30 Jun 21	29	-17	21	19
31 Mar 21	27	-16	18	20
31 Dec 20	26	-12	16	18
30 Sep 20	24	-11	15	17
30 Jun 20	24	-9	15	16
31 Mar 20	23	-11	14	17
31 Dec 19	22	-13	13	18
30 Sep 19	20	-13	13	17
30 Jun 19	18	-14	13	16
31 Mar 19	17	-11	12	14
31 Dec 18	17	-9	12	11
30 Sep 18	16	-10	11	12
30 Jun 18	15	-10	11	12
31 Mar 18	14	-10	11	12
31 Dec 17	14	-10	11	11
30 Sep 17	13	-8	11	9
30 Jun 17	13	-6	11	7
31 Mar 17	13	-5	10	6
31 Dec 16	12	-4	9	5
30 Sep 16	11	-4	8	4
30 Jun 16	11	-3	7	4
31 Mar 16	10	-3	6	3
31 Dec 15	9	-4	6	3
30 Sep 15	9	-4	6	3
30 Jun 15	8	-4	6	3
31 Mar 15	8	-4	5	3
31 Dec 14	7	-4	5	2
31 Dec 13	7	-3	5	2

質の高い収益: MXCTは現在利益が出ていません。

利益率の向上: MXCTは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: MXCTは利益が出ておらず、過去 5 年間で損失は年間27.6%の割合で増加しています。

成長の加速: MXCTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: MXCTは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( -1.7% ) と比較することは困難です。

株主資本利益率

高いROE: MXCTは現在利益が出ていないため、自己資本利益率 ( -16.15% ) はマイナスです。

MaxCyte 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Recent updates

President recently bought UK£384k worth of stock

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

Consensus estimates of losses per share improve by 16%

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

過去基準チェック /06